Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus VALISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus VALISONE.
BREO ELLIPTA vs VALISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Betamethasone valerate is a corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), which control the release of arachidonic acid from membrane phospholipids, thereby inhibiting prostaglandin and leukotriene synthesis. It has anti-inflammatory, antipruritic, and vasoconstrictive effects.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
Topical: Apply a thin layer to affected skin once or twice daily. Maximum duration: 2 weeks.
None Documented
None Documented
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Approximately 1.7 hours after topical application; systemic half-life is short due to rapid metabolism.
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Renal (primarily as metabolites, <5% unchanged); biliary/fecal elimination accounts for <10%.
Category C
Category C
Corticosteroid/Beta-2 Agonist Combination
Corticosteroid